DiNardo, C. D., Foran, J. M., Watts, J. M., Stein, E. M., Botton, S. D., Fathi, A. T., … Sallman, D. A. (2020). MDS-265: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study. In Clinical Lymphoma Myeloma and Leukemia (Vol. 20, pp. S321–S321). Elsevier BV. https://doi.org/10.1016/s2152-2650(20)30977-0

DiNardo, Courtney D., James M. Foran, Justin M. Watts, Eytan M. Stein, Stéphane de Botton, Amir T. Fathi, Gabrielle T. Prince, et al. “MDS-265: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study.” In Clinical Lymphoma Myeloma and Leukemia, 20:S321–S321. Elsevier BV, 2020. https://doi.org/10.1016/s2152-2650(20)30977-0.

DiNardo CD, Foran JM, Watts JM, Stein EM, Botton SD, Fathi AT, et al. MDS-265: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2020. p. S321–S321.

DiNardo, Courtney D., et al. “MDS-265: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 20, Elsevier BV, 2020, pp. S321–S321. Crossref, doi:10.1016/s2152-2650(20)30977-0.

DiNardo CD, Foran JM, Watts JM, Stein EM, Botton SD, Fathi AT, Prince GT, Stein AS, Stone RM, Patel PA, Roboz GJ, Arellano ML, Erba HP, Pigneux A, Stuart RK, Thomas X, Uy GL, Oluyadi A, Lemieux IR, Liu H, Wu B, Winkler T, Garcia-Manero G, Sallman DA. MDS-265: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2020. p. S321–S321.